Perfuse Therapeutics

Perfuse Therapeutics company information, Employees & Contact Information

Perfuse Therapeutics is a clinical-stage biopharmaceutical company committed to reducing the incidence of blindness. Our mission is to develop novel therapeutics to protect and improve the vision of patients with ocular diseases.

Company Details

Employees
13
Address
1700 Owens Street, Suite 540, San Francisco,ca 94158,united States
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Francisco, CA
Looking for a particular Perfuse Therapeutics employee's phone or email?

Perfuse Therapeutics Questions

News

Perfuse Therapeutics Announces Positive Results from Phase 2 Clinical Trials in Glaucoma and Diabetic Retinopathy Patients - PR Newswire

Perfuse Therapeutics Announces Positive Results from Phase 2 Clinical Trials in Glaucoma and Diabetic Retinopathy Patients PR Newswire

Perfuse Therapeutics Announces Positive Visual, Structural and Safety Data from a Ph1/2a Trial of PER-001 in Glaucoma Patients at the American Glaucoma Society Meeting - PR Newswire

Perfuse Therapeutics Announces Positive Visual, Structural and Safety Data from a Ph1/2a Trial of PER-001 in Glaucoma Patients at the American Glaucoma Society Meeting PR Newswire

Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001 - Ophthalmology Times Europe

Perfuse Therapeutics shares findings from glaucoma and diabetic retinopathy trials of PER-001 Ophthalmology Times Europe

ARVO 2025: Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma - Optometry Times

ARVO 2025: Perfuse Therapeutics announces positive results from phase 1/2a trial of PER-001, an intravitreal implant for glaucoma Optometry Times

Eye-focused biotech Perfuse Therapeutics zeroes in on pivotal studies to restore vision - The Business Journals

Eye-focused biotech Perfuse Therapeutics zeroes in on pivotal studies to restore vision The Business Journals

The Future of Glaucoma Therapy: Adaptive Trial Design and Patient-Centric Protocols - Clinical Leader

The Future of Glaucoma Therapy: Adaptive Trial Design and Patient-Centric Protocols Clinical Leader

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma - PR Newswire

Perfuse Therapeutics Announces Positive Results from the Completed Phase 1/2a Clinical Trial of PER-001 Intravitreal Implant in Patients with Glaucoma PR Newswire

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DR - Ophthalmology Times

Q&A: Sevgi Gurkan, MD, on the PER-001 for glaucoma and DR Ophthalmology Times

Perfuse Therapeutics Announces Oral Presentation on PER-001 Intravitreal Implant for Glaucoma at the Association for Research in Vision and Ophthalmology (ARVO) Meeting - PR Newswire

Perfuse Therapeutics Announces Oral Presentation on PER-001 Intravitreal Implant for Glaucoma at the Association for Research in Vision and Ophthalmology (ARVO) Meeting PR Newswire

Perfuse Therapeutics Announces Initiation of Enrollment to the Phase 2A Clinical Trial of PER001 Intravitreal Implant in Diabetic Retinopathy - PR Newswire

Perfuse Therapeutics Announces Initiation of Enrollment to the Phase 2A Clinical Trial of PER001 Intravitreal Implant in Diabetic Retinopathy PR Newswire

Top Perfuse Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant